BMS paid PsiOxus $50MM upfront for exclusive rights to develop PsiOxus’ NG-348 enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s Immuno-Oncology checkpoint inhibitor Opdivo (nivolumab) to treat a range of solid tumor types in late-stage cancer patients. This is a “big deal” – PsiOxus could receive up to $886 million in development, regulatory, and sales-based milestones, plus sales royalties. Continue reading
Tag Archives: oncolytic virus
DNAtrix and Merck Phase II Collaboration of Oncolytic Virus + Keytruda for Glioblastoma
DNAtrix and Merck announced a collaboration to combine oncolytic virus therapy and PD-1 inhibition – the two companies will collaborate in phase II clinical trials on a therapy to treat glioblastoma, an especially deadly cancer for which there is no cure. Continue reading
T-VEC Receives Advisory Committee Recommendation for Melanoma
On April 29, the FDA Oncology Drug Advisory Committee voted 22-1 to recommend approval of Amgen’s talimogene laherparepvec (T-VEC) for the treatment of patients with advanced melanoma. Continue reading